EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Christian Nelles, Moritz Gräf, Pascale Bernard, Thorsten Persigehl, Nils Große Hokamp, David Zopfs, David Maintz, Nicole Kreuzberg, Jürgen Wolf, Paul J Bröckelmann, Simon Lennartz

European Radiology · 2024

DOI: 10.1007/s00330-024-11060-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Radiology, 2024. Verfasst von Christian Nelles und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Response Evaluation Criteria in Solid Tumors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare immune response evaluation criteria in solid tumors (iRECIST) and response evaluation criteria in solid tumors (RECIST) 1.1 for response assessment of immune checkpoint inhibitor (ICI) therapy in a real-world setting in patients with melanoma and non-small cell lung cancer (NSCLC).

Methods

Two-hundred fifty-two patients with melanoma and NSCLC who received CTLA-4 inhibitor ipilimumab or PD-1 inhibitors nivolumab or pembrolizumab and who underwent staging CT of the chest and abdomen were retrospectively included. Treatment response evaluation according to the RECIST 1.1 and iRECIST guidelines was performed for all patients. Response patterns, as well as overall response rate (ORR), disease control rate (DCR), and time to progression (TTP), were compared between RECIST 1.1 and iRECIST.

Results

Out of 143 patients with progressive disease (PD) according to RECIST 1.1, 48 (33.6%) did not attain confirmation of progression (iCPD) as per iRECIST and six patients who were treated beyond RECIST 1.1 progression reached PD at a later point in time in iRECIST, resulting in a significant difference in TTP between iRECIST and RECIST 1.1 (618.3 ± 626.9 days vs. 538.1 ± 617.9 days, respectively ( p < 0.05)). The number of non-responders as per RECIST 1.1 was 79, whereas it was 60 when using iRECIST. ORR was 28.5% for RECIST 1.1 and 34.1% for iRECIST, and corresponding DCR of 67.4% for RECIST 1.1 and 74.6% for iRECIST. Conclusion iRECIST was more suitable than RECIST 1.1 for capturing atypical response patterns to ICI therapy in patients with melanoma and NSCLC, resulting in differences in the assessment of treatment response. Clinical relevance statement Compared to RECIST 1.1, iRECIST may improve patient care and treatment decisions for patients with NSCLC or melanoma who are treated with immune checkpoint inhibitors in clinical routine. Key Points RECIST 1.1 may incorrectly assess atypical treatment patterns to immune checkpoint inhibitors. iRECIST better captured atypical response patterns compared to RECIST 1.1. iRECIST was more suitable for assessing response to immune checkpoint inhibitors in non-small cell lung carcinoma and melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsResponse Evaluation Criteria in Solid TumorsMelanomaHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTomography, X-Ray ComputedNivolumabAdultAged, 80 and overAntibodies, Monoclonal, HumanizedTreatment OutcomeIpilimumab

Stichwörter der Autor:innen

Carcinoma (non-small-cell lung)Immune checkpoint inhibitorsMelanomaResponse evaluation criteria in solid tumors

Substanzen

Immune Checkpoint InhibitorspembrolizumabNivolumabAntibodies, Monoclonal, HumanizedIpilimumab

Autor:innen und Institutionen

  • Institute for Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of Dermatology and Venereology, Skin Cancer Center, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologn…
  • Institute for Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. simon.lennartz@uk-koeln.de.

Förderung

  • Else Kröner-Fresenius-Stiftung

Zitieren

APA

Nelles, C., Gräf, M., Bernard, P., Persigehl, T., Große Hokamp, N., Zopfs, D., Maintz, D., Kreuzberg, N., Wolf, J., Bröckelmann, P. J., & Lennartz, S. (2024). Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients. European Radiology. https://doi.org/10.1007/s00330-024-11060-4

Vancouver

Nelles C, Gräf M, Bernard P, Persigehl T, Große Hokamp N, Zopfs D, et al. Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients. European Radiology. 2024. doi:10.1007/s00330-024-11060-4

BibTeX
@article{Nelles2024,
  author = {Nelles, Christian and Gräf, Moritz and Bernard, Pascale and Persigehl, Thorsten and Große Hokamp, Nils and Zopfs, David and Maintz, David and Kreuzberg, Nicole and Wolf, Jürgen and Bröckelmann, Paul J and Lennartz, Simon},
  title = {Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients},
  journal = {European Radiology},
  year = {2024},
  doi = {10.1007/s00330-024-11060-4}
}
Kostenlos starten →